George A Bertolucci
Ophthalmology · Fresno
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 40 years
- Creighton University School of Medicine, 1986
Offices
2 locations · Fogg Remington Eyecare Inc · Vision Care Center A Medical Group Inc
Hospitals listed: Fresno Surgical Hospital · Saint Agnes Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call George A Bertolucci’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence G60951 · Current
Licensed to practise in California · since 1987 · expires 2027-08-31 · Creighton University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- Summit SurgicalAmbulatory Surgery Center · Fresno, CA.9 owner since 2015 · accredited by AAAHCAccreditation Renewed1 inspection, 1 with deficiencies · last 2017-05-08: Requirements Met
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Ophthalmology - Ophthalmology
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Fresno Surgical HospitalFresno, CAAcute Care Hospital · Proprietary · No emergency departmentPart of Tenet Healthcare, which runs 77 hospitals in 12 statesPatients rate it 4 of 5 · 84% would definitely recommend itNo overall ratingBetter than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 1,007 cases, Jan 2024 – Dec 2024
- Saint Agnes Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of Trinity Health, which runs 105 hospitals in 16 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.312, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.141, Oct 2024 – Sep 2025
See every measure and the patient survey for Fresno Surgical Hospital
Behind the star rating — Deaths: 0 better, 1 the same, 0 worse of 1 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 1 better, 2 the same, 0 worse of 3 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 1,007 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.09) · 413 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.82 (0.35 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.8 · 439 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 934 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 918 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.75 (0.56 to 4.94) · 938 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.6 (0 to 3.3) · 929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.27 (0.67 to 3.88) · 915 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.35 (0 to 13.68) · 929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 3.95 (0.18 to 7.73) · 899 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.22 to 3.28) · 390 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.59 (0 to 1.9) · 238 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 135 cases | None | Apr 2023 – Mar 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 129 cases | None | Jul 2023 – Jun 2025 |
What patients said (405 patients answered, 45% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 4 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 5 |
| Room was "always" clean | 81% |
| Nurses "always" communicated well | 83% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 70% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 91% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 85% |
| Nurses "always" explained things so they could understand | 79% |
| Nurses "always" listened carefully | 82% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 68% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 55% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Saint Agnes Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 6 the same, 0 worse of 8 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.312 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.141 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.18 to 1.94) · 2,342 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 197.82 (152.64 to 243.01) · 103 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.3 · 300 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.9 · 295 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.8 · 768 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.8 · 969 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 304 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 4,305 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.06 to 0.42) · 11,641 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.07 to 0.43) · 12,213 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.76 (2.91 to 6.61) · 2,466 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.09 (0 to 2.49) · 864 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.61 (0.26 to 2.96) · 2,362 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.1 (5.39 to 14.81) · 900 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.4 (1.2 to 7.59) · 882 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.84 (0.41 to 3.27) · 541 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.67 (0.14 to 1.19) · 9,626 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 58 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.835 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.182 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.004 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 412 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.6 · 1,002 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 28.8 · 296 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 25.5 · 894 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 17.8 · 981 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 1,061 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 13.4 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 412 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.3 (9.6 to 15.9) · 1,324 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 863 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 32% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$2,946,995
Medicare paid this office $2,946,995 for 1,439 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, aflibercept, 1 mg | 138 | $842,626 | None |
| Injection, pegcetacoplan, intravitreal, 1 mg | 50 | $558,917 | None |
| Injection, faricimab-svoa, 0.1 mg | 57 | $476,941 | None |
| Injection, ranibizumab, 0.1 mg | 77 | $220,884 | None |
| Injection of drug into eye | 401 | $176,774 | $86 |
See all 19 services
| Injection, aflibercept, 1 mg | 138 | $842,626 | None |
| Injection, pegcetacoplan, intravitreal, 1 mg | 50 | $558,917 | None |
| Injection, faricimab-svoa, 0.1 mg | 57 | $476,941 | None |
| Injection, ranibizumab, 0.1 mg | 77 | $220,884 | None |
| Injection of drug into eye | 401 | $176,774 | $86 |
| Injection, aflibercept hd, 1 mg | 23 | $169,670 | None |
| Unclassified drugs | 33 | $107,261 | None |
| Imaging of retina | 1,385 | $102,967 | $30 |
| Established patient complete exam of visual system | 715 | $66,656 | $86 |
| Injection, avacincaptad pegol, 0.1 mg | 11 | $60,658 | None |
| Return visit (30+ min) | 320 | $28,600 | $85 |
| Compounded drug, not otherwise classified | 103 | $27,490 | None |
| Short return visit (20+ min) | 265 | $21,520 | $61 |
| Established patient problem focused exam of visual system | 214 | $19,939 | $60 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 44 | $6,438 | $126 |
| Removal of recurring cataract in lens capsule using a laser | 13 | $3,277 | $252 |
| New patient visit (45+ min) | 26 | $3,007 | $116 |
| Photography of the retina | 56 | $1,617 | $25 |
| Exam of visual field with extended testing | 26 | $1,297 | $43 |
Procedures Medicare counted
| Cataract surgery | 19 | More than 43% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Injection of drug into eye | 2,375 | 2,131 | 2,197 | 2,421 | 2,387 | 2,055 |
| Destruction of leaking blood vessels of retina using laser | 35 | 33 | 37 | 30 | – | – |
| Removal of recurring cataract in lens capsule using a laser | 14 | 24 | 30 | 14 | 19 | 13 |
| Removal of membrane of retina | 23 | 17 | 11 | 13 | 14 | – |
| Injection of drug or substance into membrane covering eyeball | 17 | 16 | – | 13 | – | – |
| Destruction of growth of retina using a laser | 20 | – | 13 | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
1,439 Original Medicare patients in 2024. Average age 78 · Under 65 4% · 85 and older 24% · Women 59% · Also on Medicaid 14% · Health risk score 1.51. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 75% · Diabetes 42% · Coronary heart disease 42% · Chronic kidney disease 34% · Heart failure 21% · Atrial fibrillation 20% · Cancer 16% · Depression 14% · COPD 11% · Dementia 6% · Stroke 6%.
The office billed $7,086,507, Medicare allowed $3,763,717 and paid $2,946,995; for 34,924 services of 45 kinds; $2,352,878 of it was for drugs given in the office and $594,117 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,439 | 34,924 | 78 | 1.51 | $7,086,507 | $2,946,995 |
| 2023 | 1,663 | 37,488 | 78 | 1.43 | $9,107,989 | $3,506,857 |
| 2022 | 1,865 | 19,456 | 78 | 1.40 | $8,650,875 | $3,278,680 |
| 2021 | 1,864 | 17,616 | 78 | 1.42 | $7,915,235 | $3,144,163 |
| 2020 | 1,801 | 17,512 | 77 | 1.57 | $7,845,818 | $3,141,985 |
| 2019 | 2,001 | 20,758 | 77 | 1.54 | $8,912,371 | $3,670,022 |
| 2018 | 2,072 | 22,600 | 77 | 1.61 | $9,672,207 | $3,818,947 |
| 2017 | 1,930 | 20,574 | 77 | 1.57 | $8,523,432 | $3,453,908 |
| 2016 | 1,642 | 17,712 | 78 | 1.51 | $7,094,488 | $3,075,731 |
| 2015 | 1,734 | 18,498 | 78 | 1.42 | $6,669,748 | $3,317,736 |
| 2014 | 1,619 | 18,210 | 78 | 1.37 | $6,549,928 | $3,255,873 |
| 2013 | 1,418 | 16,604 | 77 | 1.35 | $5,581,318 | $2,745,622 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 20 services
| Injection, aflibercept, 1 mg | 190 | $1,315,779 | None |
| Injection, faricimab-svoa, 0.1 mg | 64 | $601,659 | None |
| Injection, ranibizumab, 0.1 mg | 131 | $539,768 | None |
| Unclassified drugs | 71 | $231,520 | None |
| Injection of drug into eye | 453 | $218,112 | $91 |
| Imaging of retina | 1,594 | $129,676 | $32 |
| Established patient problem focused exam of visual system | 471 | $114,863 | $68 |
| Established patient complete exam of visual system | 1,035 | $107,554 | $91 |
| Injection, pegcetacoplan, intravitreal, 1 mg | 23 | $83,049 | None |
| Compounded drug, not otherwise classified | 101 | $28,683 | None |
| Short return visit (20+ min) | 255 | $25,886 | $68 |
| Injection, dexamethasone, intravitreal implant, 0.1 mg | 11 | $21,128 | None |
| Removal of membrane of retina | 14 | $12,956 | $925 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 65 | $7,674 | $113 |
| Removal of recurring cataract in lens capsule using a laser | 16 | $5,387 | $284 |
| Return visit (30+ min) | 40 | $3,977 | $86 |
| New patient complete exam of visual system | 25 | $2,410 | $96 |
| Photography of the retina | 70 | $2,182 | $28 |
| Exam of visual field with extended testing | 32 | $1,795 | $45 |
| New patient visit (45+ min) | 14 | $1,378 | $98 |
2022: 23 services
| Injection, aflibercept, 1 mg | 194 | $1,565,857 | None |
| Injection, ranibizumab, 0.1 mg | 159 | $849,386 | None |
| Injection of drug into eye | 446 | $214,823 | $89 |
| Imaging of retina | 1,778 | $137,943 | $32 |
| Established patient problem focused exam of visual system | 486 | $126,866 | $67 |
| Established patient complete exam of visual system | 1,212 | $125,030 | $88 |
| Injection, faricimab-svoa, 0.1 mg | 17 | $42,972 | None |
| Compounded drug, not otherwise classified | 116 | $39,686 | None |
| Short return visit (20+ min) | 233 | $22,326 | $64 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 124 | $13,879 | $104 |
| Removal of membrane of retina | 13 | $12,089 | $930 |
| New patient visit (45+ min) | 85 | $9,815 | $115 |
| Removal of eye fluid (vitreous) between lens and retina | 12 | $9,424 | $725 |
| Destruction of leaking blood vessels of retina using laser | 13 | $8,168 | $272 |
| Return visit (30+ min) | 53 | $5,244 | $95 |
| Removal of recurring cataract in lens capsule using a laser | 13 | $3,919 | $280 |
| Photography of the retina | 121 | $3,604 | $28 |
| New patient complete exam of visual system | 18 | $2,256 | $125 |
| Exam of visual field with extended testing | 30 | $1,509 | $47 |
| 2d ultrasound scan of eye tissue and structures | 12 | $724 | $40 |
| Injection of drug or substance into membrane covering eyeball | 13 | $470 | $36 |
| Imaging of optic nerve | 19 | $426 | $22 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 13 | $37 | None |
2021: 22 services
| Injection, aflibercept, 1 mg | 165 | $1,392,445 | None |
| Injection, ranibizumab, 0.1 mg | 150 | $907,353 | None |
| Injection of drug into eye | 420 | $202,151 | $92 |
| Established patient complete exam of visual system | 1,382 | $154,043 | $93 |
| Imaging of retina | 1,772 | $143,927 | $33 |
| Established patient problem focused exam of visual system | 508 | $126,800 | $69 |
| Compounded drug, not otherwise classified | 142 | $42,224 | None |
| Short return visit (20+ min) | 206 | $26,097 | $69 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 146 | $15,629 | $100 |
| Destruction of leaking blood vessels of retina using laser | 20 | $10,566 | $286 |
| Removal of membrane of retina | 11 | $10,550 | $959 |
| Return visit (30+ min) | 72 | $7,546 | $92 |
| New patient visit (45+ min) | 50 | $6,653 | $133 |
| Destruction of growth of retina using a laser | 13 | $5,442 | $419 |
| Photography of the retina | 147 | $4,682 | $30 |
| Removal of recurring cataract in lens capsule using a laser | 16 | $4,488 | $264 |
| Short return visit | 66 | $4,334 | $40 |
| Removal of recurring cataract in lens capsule using a laser | 13 | $3,664 | $282 |
| New patient complete exam of visual system | 14 | $1,569 | $112 |
| Exam of visual field with extended testing | 26 | $1,371 | $49 |
| 2d ultrasound scan of eye tissue and structures | 12 | $545 | $42 |
| Imaging of optic nerve | 21 | $497 | $21 |
2020: 23 services
| Injection, aflibercept, 1 mg | 168 | $1,269,162 | None |
| Injection, ranibizumab, 0.1 mg | 182 | $1,087,004 | None |
| Injection of drug into eye | 433 | $175,861 | $83 |
| Established patient complete exam of visual system | 1,259 | $142,180 | $95 |
| Imaging of retina | 1,698 | $136,816 | $33 |
| Established patient problem focused exam of visual system | 542 | $133,055 | $68 |
| Compounded drug, not otherwise classified | 127 | $33,992 | None |
| Short return visit (20+ min) | 193 | $22,800 | $59 |
| Injection, brolucizumab-dbll, 1 mg | 11 | $18,104 | None |
| Removal of membrane of retina | 17 | $16,290 | $958 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 122 | $11,747 | $89 |
| Return visit (30+ min) | 93 | $8,334 | $80 |
| Removal of recurring cataract in lens capsule using a laser | 24 | $6,193 | $258 |
| Photography of the retina | 136 | $5,257 | $36 |
| Destruction of leaking blood vessels of retina using laser | 11 | $4,849 | $285 |
| Destruction of leaking blood vessels of retina using laser | 12 | $4,143 | $259 |
| New patient visit (45+ min) | 21 | $2,368 | $113 |
| New patient complete exam of visual system | 16 | $1,819 | $114 |
| Exam of visual field with extended testing | 31 | $1,505 | $47 |
| Imaging of optic nerve | 23 | $847 | $29 |
| Injection of drug or substance into membrane covering eyeball | 12 | $796 | $50 |
| 2d ultrasound scan of eye tissue and structures | 13 | $772 | $45 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 12 | $70 | None |
2019: 24 services
| Injection, ranibizumab, 0.1 mg | 219 | $1,501,096 | None |
| Injection, aflibercept, 1 mg | 152 | $1,268,898 | None |
| Injection of drug into eye | 450 | $199,797 | $84 |
| Established patient complete exam of visual system | 1,457 | $168,393 | $94 |
| Established patient problem focused exam of visual system | 628 | $164,537 | $71 |
| Imaging of retina | 1,890 | $157,631 | $33 |
| Compounded drug, not otherwise classified | 108 | $25,512 | None |
| Injection, dexamethasone, intravitreal implant, 0.1 mg | 11 | $24,044 | None |
| Removal of membrane of retina | 22 | $21,474 | $934 |
| Short return visit (20+ min) | 164 | $19,201 | $55 |
| Removal of eye fluid (vitreous) between lens and retina | 17 | $12,217 | $719 |
| Destruction of leaking blood vessels of retina using laser | 19 | $9,239 | $264 |
| Destruction of growth of retina using a laser | 17 | $8,749 | $437 |
| Return visit (30+ min) | 97 | $8,070 | $82 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 80 | $6,677 | $78 |
| Photography of the retina | 98 | $4,078 | $38 |
| Removal of recurring cataract in lens capsule using a laser | 14 | $3,484 | $249 |
| New patient complete exam of visual system | 24 | $2,609 | $109 |
| New patient visit (45+ min) | 16 | $1,809 | $113 |
| Exam of visual field with extended testing | 29 | $1,654 | $52 |
| Injection of drug or substance into membrane covering eyeball | 13 | $1,117 | $66 |
| Imaging of optic nerve | 24 | $917 | $26 |
| 2d ultrasound scan of eye tissue and structures | 13 | $779 | $41 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 12 | $81 | None |
2018: 29 services
| Injection, ranibizumab, 0.1 mg | 259 | $1,819,006 | None |
| Injection, aflibercept, 1 mg | 149 | $1,022,970 | None |
| Injection of drug into eye | 467 | $209,947 | $81 |
| Established patient problem focused exam of visual system | 724 | $180,247 | $68 |
| Established patient complete exam of visual system | 1,450 | $165,181 | $92 |
| Imaging of retina | 1,891 | $161,983 | $33 |
| Injection, dexamethasone, intravitreal implant, 0.1 mg | 12 | $29,676 | None |
| Compounded drug, not otherwise classified | 119 | $28,179 | None |
| Removal of membrane of retina | 28 | $27,908 | $900 |
| Short return visit (20+ min) | 203 | $21,760 | $53 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 19 | $18,548 | $927 |
| Destruction of growth of retina using a laser | 35 | $17,802 | $434 |
| Destruction of leaking blood vessels of retina using laser | 18 | $15,898 | $279 |
| Repair of detached retina with drainage and removal of eye fluid between lens and retina | 12 | $11,603 | $893 |
| Removal of eye fluid (vitreous) between lens and retina | 17 | $11,395 | $670 |
| Destruction of eye fluid (vitreous) between lens and retina and all of retina using a laser | 11 | $9,487 | $862 |
| Return visit (30+ min) | 90 | $7,473 | $80 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 85 | $6,879 | $71 |
| Removal of recurring cataract in lens capsule using a laser | 21 | $5,914 | $257 |
| Photography of the retina | 103 | $4,946 | $42 |
| New patient visit (45+ min) | 43 | $4,653 | $108 |
| New patient complete exam of visual system | 47 | $4,638 | $99 |
| Destruction of growth of retina using a laser | 11 | $4,320 | $393 |
| Exam of visual field with extended testing | 29 | $1,491 | $51 |
| Injection of drug or substance into membrane covering eyeball | 15 | $1,427 | $79 |
| Imaging of optic nerve | 36 | $1,198 | $27 |
| 2d ultrasound scan of eye tissue and structures | 14 | $1,149 | $60 |
| Injection, bevacizumab, 10 mg | 14 | $800 | None |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 15 | $102 | None |
2017: 25 services
| Injection, aflibercept, 1 mg | 174 | $1,358,472 | None |
| Injection, ranibizumab, 0.1 mg | 197 | $1,227,694 | None |
| Injection of drug into eye | 451 | $178,851 | $81 |
| Established patient problem focused exam of visual system | 648 | $163,907 | $65 |
| Established patient complete exam of visual system | 1,401 | $157,218 | $89 |
| Imaging of retina | 1,666 | $139,093 | $32 |
| Removal of membrane of retina | 31 | $29,085 | $938 |
| Injection, dexamethasone, intravitreal implant, 0.1 mg | 14 | $27,685 | None |
| Destruction of growth of retina using a laser | 42 | $21,508 | $430 |
| Compounded drug, not otherwise classified | 110 | $17,910 | None |
| Short return visit (20+ min) | 146 | $17,345 | $54 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 11 | $10,022 | $835 |
| Removal of eye fluid (vitreous) between lens and retina | 13 | $8,931 | $687 |
| Photography of the retina | 131 | $7,505 | $52 |
| Removal of recurring cataract in lens capsule using a laser | 29 | $7,201 | $240 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 85 | $5,969 | $65 |
| Destruction of leaking blood vessels of retina using laser | 12 | $5,357 | $282 |
| New patient visit (45+ min) | 41 | $4,778 | $117 |
| New patient complete exam of visual system | 37 | $4,283 | $116 |
| Injection, triamcinolone acetonide, preservative free, 1 mg | 12 | $2,981 | None |
| Return visit (30+ min) | 31 | $2,572 | $83 |
| Exam of visual field with extended testing | 38 | $1,945 | $49 |
| Imaging of optic nerve | 37 | $1,411 | $28 |
| Injection of drug or substance into membrane covering eyeball | 11 | $861 | $78 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 11 | $63 | None |
2016: 19 services
| Injection, ranibizumab, 0.1 mg | 219 | $1,531,182 | None |
| Injection, aflibercept, 1 mg | 97 | $781,575 | None |
| Established patient problem focused exam of visual system | 633 | $167,184 | $66 |
| Injection of drug into eye | 356 | $156,525 | $82 |
| Established patient complete exam of visual system | 1,209 | $140,404 | $90 |
| Imaging of retina | 1,384 | $132,789 | $36 |
| Destruction of growth of retina using a laser | 64 | $32,381 | $421 |
| Injection, dexamethasone, intravitreal implant, 0.1 mg | 16 | $25,523 | None |
| Removal of membrane of retina | 21 | $20,766 | $944 |
| Compounded drug, not otherwise classified | 59 | $10,509 | None |
| Removal of eye fluid (vitreous) between lens and retina | 13 | $9,566 | $736 |
| Removal of recurring cataract in lens capsule using a laser | 28 | $7,836 | $261 |
| New patient complete exam of visual system | 55 | $6,177 | $112 |
| Destruction of leaking blood vessels of retina using laser | 13 | $5,929 | $282 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 49 | $5,749 | $90 |
| Photography of the retina | 83 | $5,237 | $60 |
| Exam of visual field with extended testing | 37 | $2,006 | $51 |
| Imaging of optic nerve | 41 | $1,855 | $34 |
| Injection, triamcinolone acetonide, preservative free, 1 mg | 13 | $1,745 | None |
2015: 19 services
| Injection, ranibizumab, 0.1 mg | 247 | $1,735,142 | None |
| Injection, aflibercept, 1 mg | 106 | $802,502 | None |
| Established patient problem focused exam of visual system | 718 | $183,019 | $67 |
| Injection of drug into eye | 402 | $167,237 | $82 |
| Imaging of retina | 1,450 | $140,304 | $36 |
| Established patient complete exam of visual system | 1,180 | $131,886 | $90 |
| Destruction of leaking blood vessels of retina using laser | 22 | $22,078 | $818 |
| Removal of membrane of retina | 21 | $19,460 | $927 |
| New patient complete exam of visual system | 93 | $9,511 | $102 |
| Removal of recurring cataract in lens capsule using a laser | 33 | $8,330 | $252 |
| Unclassified biologics | 58 | $7,970 | None |
| Exam of retinal blood vessels using a special camera after injection of a dye | 57 | $7,814 | $89 |
| Photocoagulation treatment to prevent detachment of retina | 14 | $6,466 | $431 |
| Photography of the retina | 35 | $2,359 | $64 |
| Compounded Drug, Not Otherwise Classified | 26 | $2,292 | $55 |
| Short return visit (20+ min) | 37 | $1,514 | $34 |
| Exam of visual field with extended testing | 23 | $1,128 | $47 |
| Imaging of optic nerve | 26 | $1,085 | $36 |
| Injection, triamcinolone acetonide, preservative free, 1 mg | 13 | $1,060 | None |
2014: 20 services
| Injection, ranibizumab, 0.1 mg | 277 | $2,029,120 | None |
| Injection, aflibercept, 1 mg | 67 | $444,437 | None |
| Established patient problem focused exam of visual system | 623 | $172,415 | $68 |
| Injection of drug into eye | 379 | $170,739 | $84 |
| Established patient complete exam of visual system | 1,148 | $136,085 | $91 |
| Imaging of retina | 1,322 | $134,887 | $37 |
| Removal of membrane of retina | 26 | $30,980 | $1,106 |
| Destruction of leaking blood vessels of retina using laser | 21 | $26,045 | $840 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 66 | $9,000 | $87 |
| New patient complete exam of visual system | 69 | $7,776 | $113 |
| Photocoagulation treatment to prevent detachment of retina | 14 | $6,604 | $440 |
| Unclassified biologics | 57 | $6,392 | None |
| Destruction of growth of retina using a laser | 13 | $5,678 | $437 |
| Removal of recurring cataract in lens capsule using a laser | 18 | $4,834 | $242 |
| Photography of the retina | 35 | $2,309 | $66 |
| New patient visit (45+ min) | 18 | $2,303 | $128 |
| Injection, bevacizumab, 10 mg | 27 | $2,162 | None |
| Short return visit (20+ min) | 30 | $1,431 | $48 |
| Exam of visual field with extended testing | 22 | $1,134 | $52 |
| Imaging of optic nerve | 28 | $1,020 | $33 |
2013: 19 services
| Injection, ranibizumab, 0.1 mg | 267 | $1,803,147 | None |
| Injection, aflibercept, 1 mg | 52 | $227,113 | None |
| Established patient problem focused exam of visual system | 666 | $153,140 | $67 |
| Injection of drug into eye | 351 | $145,245 | $84 |
| Imaging of retina | 1,058 | $113,031 | $36 |
| Established patient complete exam of visual system | 906 | $100,556 | $91 |
| Unclassified drugs | 12 | $35,497 | None |
| Removal of membrane of retina | 20 | $23,066 | $1,098 |
| Destruction of leaking blood vessels of retina using laser | 23 | $22,507 | $776 |
| New patient complete exam of visual system | 68 | $7,972 | $117 |
| Injection, bevacizumab, 10 mg | 44 | $7,779 | None |
| Removal of recurring cataract in lens capsule using a laser | 30 | $7,763 | $250 |
| Photocoagulation treatment to prevent detachment of retina | 16 | $7,464 | $439 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 54 | $7,055 | $89 |
| Destruction of growth of retina using a laser | 12 | $6,120 | $437 |
| Short return visit (20+ min) | 46 | $2,917 | $57 |
| Exam of visual field with extended testing | 20 | $1,159 | $55 |
| Photography of the retina | 15 | $847 | $56 |
| Imaging of optic nerve | 19 | $748 | $36 |
Medicaid work
$7,549 in 2024
Medicaid paid $7,549 for 765 billed services this clinician did in 2024, up to 50 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Intravitreal injection of a pharmacologic agent (separate procedure) | 258 | $5,701 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 452 | $1,496 |
| Short return visit (20+ min) | 12 | $211 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 15 | $100 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 28 | $41 |
| 2024 | 765 | 5 | 50 | $7,549 |
| 2023 | 2,049 | 6 | 55 | $17,653 |
| 2022 | 1,550 | 4 | 41 | $10,549 |
| 2021 | 720 | 4 | 31 | $2,462 |
| 2020 | 575 | 5 | 31 | $1,825 |
| 2019 | 678 | 5 | 40 | $3,441 |
| 2018 | 1,814 | 6 | 64 | $9,021 |
See the largest Medicaid services in earlier years
2023
| Intravitreal injection of a pharmacologic agent (separate procedure) | 703 | $14,968 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 909 | $1,960 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 309 | $541 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 62 | $123 |
| Short return visit (20+ min) | 26 | $60 |
| Injection, bevacizumab, 10 mg | 40 | $0 |
2022
| Intravitreal injection of a pharmacologic agent (separate procedure) | 477 | $8,775 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 312 | $997 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 748 | $777 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 13 | $0 |
2021
| Intravitreal injection of a pharmacologic agent (separate procedure) | 158 | $951 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 155 | $948 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 392 | $439 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 15 | $124 |
2020
| Intravitreal injection of a pharmacologic agent (separate procedure) | 119 | $732 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 282 | $588 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 140 | $471 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 15 | $35 |
| Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 19 | $0 |
2019
| Intravitreal injection of a pharmacologic agent (separate procedure) | 156 | $1,962 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 300 | $902 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 166 | $543 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 12 | $35 |
| Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 44 | $0 |
2018
| Intravitreal injection of a pharmacologic agent (separate procedure) | 547 | $4,661 |
| Ranibizumab injection | 91 | $1,493 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 753 | $1,371 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 358 | $1,322 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 52 | $138 |
| Short return visit (20+ min) | 13 | $37 |
Drugs they prescribed that Part D paid
$59,237
Pharmacies billed $59,237 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 789) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
443 generic and 346 brand-name prescriptions · $59,237 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lumigan | 31 | $14,436 | $466 |
| Prednisolone Acetate | 170 | $7,489 | $44 |
| Brimonidine | 64 | $6,551 | $102 |
| Alphagan P | 17 | $3,909 | $230 |
| Cyclosporine | 16 | $2,694 | $168 |
See all 11 drugs
| Lumigan | 31 | $14,436 | $466 |
| Prednisolone Acetate | 170 | $7,489 | $44 |
| Brimonidine | 64 | $6,551 | $102 |
| Alphagan P | 17 | $3,909 | $230 |
| Cyclosporine | 16 | $2,694 | $168 |
| Latanoprost | 199 | $2,574 | $13 |
| Timolol Maleate | 84 | $1,262 | $15 |
| Ofloxacin | 45 | $693 | $15 |
| Ketorolac Tromethamine | 28 | $535 | $19 |
| Dorzolamide-Timolol | 22 | $485 | $22 |
| Neomycin-Polymyxin-Dexameth | 17 | $370 | $22 |
Year by year
| 2024 | 789 | 229 | 0% (0) | 44% | $59,237 |
| 2023 | 939 | 266 | 0% (0) | 49% | $92,042 |
| 2022 | 1,052 | 279 | 0% (0) | 52% | $98,173 |
| 2021 | 981 | 286 | 0% (0) | 48% | $84,355 |
| 2020 | 1,150 | 315 | 0% (0) | 46% | $112,002 |
| 2019 | 1,017 | 295 | 0% (0) | 43% | $101,926 |
| 2018 | 1,292 | 339 | None | 46% | $126,960 |
| 2017 | 1,006 | 280 | 0% (0) | 45% | $103,210 |
| 2016 | 767 | 216 | 0% (0) | 51% | $87,236 |
| 2015 | 724 | 195 | None | 57% | $87,648 |
| 2014 | 671 | 180 | None | 56% | $71,118 |
| 2013 | 629 | 174 | 0% (0) | 60% | $64,287 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 16 drugs
| Lumigan | 26 | $11,492 | $442 |
| Restasis | 14 | $9,765 | $698 |
| Alphagan P | 39 | $8,747 | $224 |
| Prednisolone Acetate | 190 | $8,240 | $43 |
| Brimonidine | 49 | $5,078 | $104 |
| Prolensa | 12 | $4,870 | $406 |
| Latanoprost | 218 | $4,618 | $21 |
| Combigan | 14 | $2,807 | $201 |
| Difluprednate | 13 | $2,167 | $167 |
| Timolol Maleate | 115 | $2,077 | $18 |
| Ofloxacin | 46 | $783 | $17 |
| Ketorolac Tromethamine | 30 | $723 | $24 |
| Dorzolamide-Timolol | 35 | $688 | $20 |
| Neomycin-Polymyxin-Dexameth | 16 | $300 | $19 |
| Polymyxin B Sul-Trimethoprim | 11 | $116 | $11 |
| Prednisone | 12 | $73 | $6 |
2022: 15 drugs
| Lumigan | 27 | $11,492 | $426 |
| Prednisolone Acetate | 233 | $10,402 | $45 |
| Restasis | 12 | $9,957 | $830 |
| Alphagan P | 42 | $8,926 | $213 |
| Latanoprost | 283 | $5,895 | $21 |
| Ilevro | 15 | $4,686 | $312 |
| Prolensa | 11 | $4,363 | $397 |
| Combigan | 15 | $3,037 | $202 |
| Travoprost | 13 | $2,133 | $164 |
| Timolol Maleate | 122 | $1,599 | $13 |
| Ofloxacin | 86 | $1,250 | $15 |
| Brimonidine | 19 | $1,215 | $64 |
| Ketorolac Tromethamine | 31 | $1,106 | $36 |
| Dorzolamide-Timolol | 19 | $750 | $39 |
| Erythromycin | 13 | $155 | $12 |
2021: 14 drugs
| Restasis | 17 | $16,036 | $943 |
| Lumigan | 24 | $9,455 | $394 |
| Prednisolone Acetate | 174 | $8,897 | $51 |
| Alphagan P | 36 | $7,350 | $204 |
| Latanoprost | 300 | $6,282 | $21 |
| Prolensa | 16 | $5,566 | $348 |
| Travoprost | 16 | $3,577 | $224 |
| Betimol | 12 | $1,818 | $152 |
| Timolol Maleate | 120 | $1,412 | $12 |
| Ofloxacin | 73 | $1,045 | $14 |
| Olopatadine | 14 | $920 | $66 |
| Dorzolamide-Timolol | 20 | $731 | $37 |
| Neomycin-Polymyxin-Dexameth | 21 | $522 | $25 |
| Polymyxin B Sul-Trimethoprim | 11 | $92 | $8 |
2020: 22 drugs
| Restasis | 19 | $17,410 | $916 |
| Pazeo | 47 | $14,234 | $303 |
| Lumigan | 27 | $9,489 | $351 |
| Prednisolone Acetate | 185 | $8,839 | $48 |
| Alphagan P | 44 | $8,105 | $184 |
| Prolensa | 23 | $6,796 | $295 |
| Latanoprost | 299 | $5,432 | $18 |
| Travatan Z | 15 | $5,069 | $338 |
| Durezol | 18 | $4,027 | $224 |
| Travoprost | 12 | $2,859 | $238 |
| Lotemax | 13 | $2,672 | $206 |
| Betimol | 12 | $1,822 | $152 |
| Olopatadine | 24 | $1,765 | $74 |
| Bacitracin | 13 | $1,204 | $93 |
| Brimonidine | 25 | $1,112 | $44 |
| Timolol Maleate | 133 | $1,067 | $8 |
| Ofloxacin | 66 | $1,040 | $16 |
| Dorzolamide-Timolol | 15 | $872 | $58 |
| Neomycin-Polymyxin-Dexameth | 29 | $807 | $28 |
| Azelastine | 14 | $362 | $26 |
| Erythromycin | 15 | $196 | $13 |
| Polymyxin B Sul-Trimethoprim | 13 | $117 | $9 |
2019: 17 drugs
| Pazeo | 46 | $11,613 | $252 |
| Travatan Z | 24 | $8,514 | $355 |
| Durezol | 41 | $8,325 | $203 |
| Lumigan | 18 | $7,113 | $395 |
| Alphagan P | 29 | $6,129 | $211 |
| Prolensa | 21 | $5,710 | $272 |
| Latanoprost | 282 | $5,653 | $20 |
| Prednisolone Acetate | 120 | $5,208 | $43 |
| Lotemax | 23 | $4,706 | $205 |
| Olopatadine | 30 | $3,923 | $131 |
| Simbrinza | 16 | $2,555 | $160 |
| Ofloxacin | 73 | $1,400 | $19 |
| Dorzolamide-Timolol | 25 | $987 | $39 |
| Timolol Maleate | 104 | $647 | $6 |
| Azelastine | 18 | $645 | $36 |
| Neomycin-Polymyxin-Dexameth | 18 | $475 | $26 |
| Brimonidine | 13 | $379 | $29 |
2018: 18 drugs
| Durezol | 103 | $18,503 | $180 |
| Lumigan | 23 | $9,621 | $418 |
| Travatan Z | 26 | $9,259 | $356 |
| Ilevro | 16 | $8,594 | $537 |
| Prolensa | 30 | $8,022 | $267 |
| Alphagan P | 45 | $7,627 | $169 |
| Prednisolone Acetate | 137 | $6,318 | $46 |
| Latanoprost | 332 | $6,201 | $19 |
| Pazeo | 27 | $5,520 | $204 |
| Lotemax | 25 | $5,237 | $209 |
| Olopatadine | 52 | $4,788 | $92 |
| Ofloxacin | 104 | $1,769 | $17 |
| Bacitracin | 11 | $898 | $82 |
| Neomycin-Polymyxin-Dexameth | 43 | $875 | $20 |
| Timolol Maleate | 106 | $813 | $8 |
| Dorzolamide-Timolol | 32 | $737 | $23 |
| Brimonidine | 22 | $717 | $33 |
| Dorzolamide | 18 | $344 | $19 |
2017: 19 drugs
| Travatan Z | 48 | $12,452 | $259 |
| Lumigan | 28 | $10,713 | $383 |
| Durezol | 61 | $10,072 | $165 |
| Pataday | 35 | $8,476 | $242 |
| Alphagan P | 53 | $7,848 | $148 |
| Prednisolone Acetate | 91 | $4,482 | $49 |
| Latanoprost | 247 | $4,177 | $17 |
| Prolensa | 12 | $3,212 | $268 |
| Pazeo | 14 | $3,137 | $224 |
| Olopatadine | 29 | $2,849 | $98 |
| Tobramycin-Dexamethasone | 15 | $1,934 | $129 |
| Ofloxacin | 66 | $1,072 | $16 |
| Brimonidine | 17 | $983 | $58 |
| Neomycin-Polymyxin-Dexameth | 30 | $654 | $22 |
| Timolol Maleate | 75 | $468 | $6 |
| Dorzolamide-Timolol | 26 | $452 | $17 |
| Diclofenac | 11 | $153 | $14 |
| Polymyxin B Sul-Trimethoprim | 18 | $149 | $8 |
| Dorzolamide | 13 | $144 | $11 |
2016: 14 drugs
| Lumigan | 48 | $15,378 | $320 |
| Travatan Z | 36 | $9,841 | $273 |
| Pataday | 39 | $8,668 | $222 |
| Durezol | 53 | $8,208 | $155 |
| Combigan | 41 | $6,076 | $148 |
| Prednisolone Acetate | 68 | $4,947 | $73 |
| Latanoprost | 170 | $3,122 | $18 |
| Pazeo | 11 | $3,069 | $279 |
| Alphagan P | 20 | $2,957 | $148 |
| Timolol Maleate | 75 | $733 | $10 |
| Olopatadine | 11 | $651 | $59 |
| Neomycin-Polymyxin-Dexameth | 29 | $628 | $22 |
| Dorzolamide-Timolol | 24 | $468 | $20 |
| Polymyxin B Sul-Trimethoprim | 47 | $437 | $9 |
2015: 14 drugs
| Lumigan | 47 | $13,297 | $283 |
| Restasis | 20 | $10,953 | $548 |
| Pataday | 42 | $9,710 | $231 |
| Prednisolone Acetate | 99 | $7,562 | $76 |
| Travatan Z | 32 | $6,357 | $199 |
| Azopt | 17 | $5,413 | $318 |
| Combigan | 30 | $4,057 | $135 |
| Alphagan P | 19 | $2,743 | $144 |
| Latanoprost | 142 | $2,374 | $17 |
| Tobramycin-Dexamethasone | 20 | $2,261 | $113 |
| Timolol Maleate | 53 | $1,832 | $35 |
| Durezol | 11 | $1,811 | $165 |
| Dorzolamide-Timolol | 26 | $661 | $25 |
| Polymyxin B Sul-Trimethoprim | 52 | $500 | $10 |
2014: 15 drugs
| Pataday | 59 | $10,770 | $183 |
| Lumigan | 41 | $9,777 | $238 |
| Restasis | 17 | $8,203 | $483 |
| Travatan Z | 32 | $6,275 | $196 |
| Prednisolone Acetate | 63 | $4,993 | $79 |
| Combigan | 38 | $4,436 | $117 |
| Azopt | 15 | $3,361 | $224 |
| Bepreve | 11 | $2,181 | $198 |
| Durezol | 16 | $2,025 | $127 |
| Latanoprost | 119 | $1,880 | $16 |
| Tobramycin-Dexamethasone | 20 | $1,852 | $93 |
| Timolol Maleate | 59 | $1,071 | $18 |
| Dorzolamide-Timolol | 35 | $1,041 | $30 |
| Polymyxin B Sul-Trimethoprim | 25 | $253 | $10 |
| Ofloxacin | 20 | $162 | $8 |
2013: 16 drugs
| Lumigan | 50 | $10,883 | $218 |
| Pataday | 49 | $9,103 | $186 |
| Restasis | 14 | $5,866 | $419 |
| Travatan Z | 36 | $5,813 | $161 |
| Patanol | 27 | $4,717 | $175 |
| Azopt | 11 | $2,800 | $255 |
| Prednisolone Acetate | 51 | $1,899 | $37 |
| Latanoprost | 80 | $1,759 | $22 |
| Combigan | 17 | $1,652 | $97 |
| Vigamox | 11 | $1,427 | $130 |
| Durezol | 11 | $1,427 | $130 |
| Tobramycin-Dexamethasone | 13 | $1,253 | $96 |
| Dorzolamide-Timolol | 34 | $1,098 | $32 |
| Timolol Maleate | 48 | $910 | $19 |
| Bacitracin | 11 | $631 | $57 |
| Ofloxacin | 44 | $322 | $7 |
Money from drug and device companies
$788 in 2025
| 2025 | 5 | 26 | None | $788 |
| 2024 | 7 | 37 | None | $1,304 |
| 2023 | 9 | 34 | $4,003 | $5,288 |
| 2022 | 6 | 23 | None | $658 |
| 2021 | 7 | 18 | None | $511 |
| 2020 | 4 | 10 | None | $190 |
| 2019 | 9 | 50 | None | $836 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Astellas Pharma US | Izervay | $348 | 15 payments
|
| Apellis Pharmaceuticals | Syfovre | $191 | 6 payments
|
| Regeneron Pharmaceuticals | Eylea Hd | $124 | 1 payment
|
| Abbvie | Durysta | $98 | 3 payments
|
| Genentech USA | Vabysmo | $26 | 1 payment
|
See all 26 published payments
| Astellas Pharma US | Meals · 2025-12-22 | Izervay | $23 |
| Astellas Pharma US | Meals · 2025-12-16 | Izervay | $5 |
| Astellas Pharma US | Meals · 2025-11-18 | Izervay | $18 |
| Apellis Pharmaceuticals | Meals · 2025-09-18 | Syfovre | $23 |
| Apellis Pharmaceuticals | Meals · 2025-09-17 | Syfovre | $5 |
| Astellas Pharma US | Meals · 2025-08-27 | Izervay | $30 |
| Astellas Pharma US | Meals · 2025-08-12 | Izervay | $21 |
| Astellas Pharma US | Meals · 2025-07-31 | Izervay | $14 |
| Astellas Pharma US | Meals · 2025-06-25 | Izervay | $27 |
| Astellas Pharma US | Meals · 2025-06-24 | Izervay | $28 |
| Apellis Pharmaceuticals | Meals · 2025-06-20 | Syfovre | $25 |
| Apellis Pharmaceuticals | Meals · 2025-06-13 | Syfovre | $2 |
| Astellas Pharma US | Meals · 2025-05-28 | Izervay | $25 |
| Astellas Pharma US | Meals · 2025-05-27 | Izervay | $28 |
| Apellis Pharmaceuticals | Meals · 2025-05-14 | Syfovre | $125 |
| Abbvie | Meals · 2025-04-26 | Durysta | $35 |
| Abbvie | Meals · 2025-04-24 | Durysta | $29 |
| Astellas Pharma US | Meals · 2025-04-22 | Izervay | $16 |
| Regeneron Pharmaceuticals | Meals · 2025-04-10 | Eylea Hd | $124 |
| Astellas Pharma US | Meals · 2025-03-26 | Izervay | $25 |
| Abbvie | Meals · 2025-03-19 | Durysta | $34 |
| Astellas Pharma US | Meals · 2025-02-19 | Izervay | $30 |
| Astellas Pharma US | Meals · 2025-02-18 | Izervay | $32 |
| Apellis Pharmaceuticals | Meals · 2025-02-12 | Syfovre | $12 |
| Genentech USA | Meals · 2025-01-23 | Vabysmo | $26 |
| Astellas Pharma US | Meals · 2025-01-08 | Izervay | $26 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,304
| Astellas Pharma US | Izervay | $498 | 11 payments
|
| Genentech USA | Vabysmo | $346 | 15 payments
|
| Regeneron Healthcare Solutions | Eylea Hd | $266 | 3 payments
|
| Abbvie | Durysta | $78 | 3 payments
|
| Apellis Pharmaceuticals | Syfovre | $59 | 3 payments
|
| Biogen | Byooviz | $29 | 1 payment
|
| Dompe US | Oxervate | $27 | 1 payment
|
2023: $5,288
| Alexion Pharmaceuticals | None | $4,003 | 2 payments
|
| Mallinckrodt Hospital Products | Acthar | $281 | 4 payments
|
| Regeneron Healthcare Solutions | Eylea | $273 | 3 payments
|
| Genentech USA | Vabysmo | $236 | 11 payments
|
| Alimera Sciences | Iluvien | $159 | 4 payments
|
| Astellas Pharma US | None | $126 | 4 payments
|
| Regeneron Pharmaceuticals | Eylea | $106 | 1 payment
|
| Apellis Pharmaceuticals | Syfovre | $87 | 4 payments
|
| AbbVie | Ozurdex | $17 | 1 payment
|
2022: $658
| Genentech USA | Vabysmo | $187 | 13 payments
|
| Regeneron Healthcare Solutions | Eylea | $164 | 3 payments
|
| EyePoint Pharmaceuticals US | Yutiq | $142 | 2 payments
|
| Apellis Pharmaceuticals | None | $133 | 3 payments
|
| Alimera Sciences | Iluvien | $16 | 1 payment
|
| Abbvie | Ozurdex | $15 | 1 payment
|
2021: $511
| Regeneron Healthcare Solutions | Eylea | $133 | 2 payments
|
| Aerie Pharmaceuticals | Rhopressa | $129 | 3 payments
|
| Tissuetech | Prokera | $100 | 6 payments
|
| Genentech USA | Lucentis | $71 | 3 payments
|
| Allergan | Ozurdex | $40 | 2 payments
|
| EyePoint Pharmaceuticals US | Dexycu | $23 | 1 payment
|
| Alimera Sciences | Iluvien | $15 | 1 payment
|
2020: $190
| TissueTech | Prokera | $72 | 4 payments
|
| Allergan | Ozurdex | $50 | 3 payments
|
| Genentech USA | Lucentis | $49 | 2 payments
|
| Alimera Sciences | Iluvien | $19 | 1 payment
|
2019: $836
| Novartis Pharmaceuticals | Beovu | $231 | 7 payments
|
| Alimera Sciences | Iluvien | $159 | 3 payments
|
| Regeneron Healthcare Solutions | Eylea | $153 | 3 payments
|
| Regeneron Pharmaceuticals | Eylea | $89 | 1 payment
|
| Genentech USA | Lucentis | $74 | 4 payments
|
| Sun Pharmaceutical Industries | Cequa | $67 | 1 payment
|
| Bausch & Lomb a division of Bausch Health US | Visudyne | $30 | 2 payments
|
| Allergan | Ozurdex | $19 | 1 payment
|
| TissueTech | Prokera | $14 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Genentech, Inc. · Va2 Phiii Yosemite · 2020 | This clinician | $22,023 |
| Astellas Pharma Global Development · An Open-Label Extension (Ole) Phase 3 Trial To Assess the Safety of Intravitreal Administration of Avacincaptad Pegol (Complement C5 Inhibitor) in Patients With Geographic Atrophy Who Previously Completed Phase 3 Study Isee2008 (Gather2) · 2023 | Their institution | $17,771 |
| Genentech, Inc. · Va2 Phiii Yosemite · 2019 | This clinician | $15,769 |
| Genentech, Inc. · Faricimab Dme Long Term Extension Rhone X · 2022 | This clinician | $15,288 |
| Novartis Pharmaceuticals Corporation · A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Vs. Aflibercept in Patients With Visual Impairment Due To Diabetic Macular Edema (Kingfisher) · 2020 | Their institution | $15,275 |
| Novartis Pharmaceuticals Corporation · A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Vs. Aflibercept in Patients With Visual Impairment Due To Diabetic Macular Edema (Kingfisher) · 2019 | Their institution | $12,130 |
| Genentech, Inc. · Va2 Phiii Yosemite · 2021 | This clinician | $11,741 |
| Alexion Pharmaceuticals, Inc. · A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (Alxn2040) in Patients With Geographic Atrophy (Ga) Secondary To Age Related Macular Degeneration (Amd) · 2024 | This clinician | $4,863 |
| Genentech, Inc. · Faricimab Dme Long Term Extension Rhone X · 2023 | This clinician | $4,608 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 89.9 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1447267505
- Licence
- CA G60951California G60951: Current · expires 2027-08-31
- Trained
- Creighton University School of Medicine, 1986 · 40 years ago
- Group
- Fogg Remington Eyecare Inc · Vision Care Center A Medical Group Inc
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G609510
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 1360 E Herndon Avenue, Suite 301, Fresno, CA, 93720
- NPI first listed
- 2006-08-02
- NPI last updated
- 2007-07-08
This is when the NPI record was last certified, not a medical board exam.